Aviva, Axon in biochip development program
Biochip company Aviva Biosciences will make a $3.5mm equity investment in Axon Instruments (drug discovery technologies that combine biochips and cell biology) in exchange for an exclusive license to intellectual property and patch clamp biochips.
- Research, Analytical Equipment & Supplies
- Nanotechnology, Chips, etc.
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com